"HIV Protease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene.
| Descriptor ID |
D016333
|
| MeSH Number(s) |
D08.811.277.656.074.500.340 D08.811.277.656.300.048.340 D12.776.964.775.375.545.750
|
| Concept/Terms |
HIV Protease- HIV Protease
- Protease, HIV
- p16 pol gene product, HIV
- p16 protease, HIV
- HIV p16 protease
- HIV Proteinase
- HTLV-III Protease
- HTLV III Protease
- Protease, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease".
This graph shows the total number of publications written about "HIV Protease" by people in this website by year, and whether "HIV Protease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Protease" by people in Profiles.
-
Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naïve Sequences. AIDS Res Hum Retroviruses. 2019 07; 35(7):673-678.
-
Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. Biochem J. 2019 01 31; 476(2):375-384.
-
Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant. Antivir Ther. 2019; 24(5):333-342.
-
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2248-56.
-
Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
-
Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. J Clin Virol. 2012 May; 54(1):21-5.
-
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
-
Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study. J Virol. 2008 Nov; 82(22):11476-9.
-
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008; 13 Suppl 2:101-7.
-
Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1306-12.